232 related articles for article (PubMed ID: 16567036)
41. Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
Arnold NJ; Arnold R; Beer D; Bhalay G; Collingwood SP; Craig S; Devereux N; Dodds M; Dunstan AR; Fairhurst RA; Farr D; Fullerton JD; Glen A; Gomez S; Haberthuer S; Hatto JD; Howes C; Jones D; Keller TH; Leuenberger B; Moser HE; Muller I; Naef R; Nicklin PA; Sandham DA; Turner KL; Tweed MF; Watson SJ; Zurini M
Bioorg Med Chem Lett; 2007 Apr; 17(8):2376-9. PubMed ID: 17337182
[TBL] [Abstract][Full Text] [Related]
42. Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association?
Schiefer J; Sparing R
Int J Impot Res; 2005; 17(4):383-4. PubMed ID: 15674402
[TBL] [Abstract][Full Text] [Related]
43. Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6.
Pissarnitski D
Med Res Rev; 2006 May; 26(3):369-95. PubMed ID: 16388517
[TBL] [Abstract][Full Text] [Related]
44. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.
Bella AJ; Brant WO; Lue TF; Brock GB
Can J Urol; 2006 Oct; 13(5):3233-8. PubMed ID: 17076943
[TBL] [Abstract][Full Text] [Related]
45. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
Greco EA; Spera G; Aversa A
Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
[TBL] [Abstract][Full Text] [Related]
46. [The treatment options broaden. New chances for libido].
Einecke U
MMW Fortschr Med; 2002 May; 144(19):4-6. PubMed ID: 12116552
[No Abstract] [Full Text] [Related]
47. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
48. [Therapeutic efficacy of a course administration of vardenafil--inhibitor of phosphodiesterase-5--in erectile dysfunction].
Aliaev IuG; Vinarov AZ; Akhvlediani ND
Urologiia; 2007; (1):45-6, 49. PubMed ID: 17471999
[TBL] [Abstract][Full Text] [Related]
49. Visual loss associated with erectile dysfunction drugs.
Dündar SO
Can J Ophthalmol; 2007 Feb; 42(1):10-2. PubMed ID: 17361234
[No Abstract] [Full Text] [Related]
50. Prevalence of phosphodiesterase-5 inhibitor use in the VHA in 2004 and 2005 is twice that of a commercial health plan in 2001.
French DD; Margo CE; Campbell RR
J Manag Care Pharm; 2006 Oct; 12(8):692-3. PubMed ID: 17269850
[No Abstract] [Full Text] [Related]
51. Gene therapy and erectile dysfunction: the current status.
Lau DH; Kommu SS; Siddiqui EJ; Thompson CS; Morgan RJ; Mikhailidis DP; Mumtaz FH
Asian J Androl; 2007 Jan; 9(1):8-15. PubMed ID: 16888683
[TBL] [Abstract][Full Text] [Related]
52. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat.
Ferrini MG; Kovanecz I; Sanchez S; Vernet D; Davila HH; Rajfer J; Gonzalez-Cadavid NF
Biol Reprod; 2007 May; 76(5):915-23. PubMed ID: 17287493
[TBL] [Abstract][Full Text] [Related]
53. Ophthalmic aspects of erectile dysfunction drugs.
Verit A; Oguz H
Am J Ophthalmol; 2006 Mar; 141(3):598; author reply 599. PubMed ID: 16490529
[No Abstract] [Full Text] [Related]
54. The multinational Men's Attitudes to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns, among men with erectile dysfunction.
Fisher WA; Rosen RC; Eardley I; Niederberger C; Nadel A; Kaufman J; Sand M
J Sex Med; 2004 Sep; 1(2):150-60. PubMed ID: 16422969
[TBL] [Abstract][Full Text] [Related]
55. Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
Yu G; Mason HJ; Wu X; Wang J; Chong S; Dorough G; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Adam L; Krupinski J; Macor JE
J Med Chem; 2001 Mar; 44(7):1025-7. PubMed ID: 11297448
[No Abstract] [Full Text] [Related]
56. The use of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Montorsi F; Briganti A; Salonia A; Montorsi P; Rigatti P
Curr Opin Urol; 2004 Nov; 14(6):357-9. PubMed ID: 15626879
[No Abstract] [Full Text] [Related]
57. PDE5 inhibition and fibrosis.
Corbin J
Int J Impot Res; 2005; 17(6):546. PubMed ID: 16258527
[TBL] [Abstract][Full Text] [Related]
58. Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
Yu G; Mason H; Wu X; Wang J; Chong S; Beyer B; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Ferrer P; Zhang R; Adam L; Humphrey WG; Krupinski J; Macor JE
J Med Chem; 2003 Feb; 46(4):457-60. PubMed ID: 12570368
[TBL] [Abstract][Full Text] [Related]
59. Chapter 1: The management of erectile dysfunction: an AUA update.
Montague DK; Jarow JP; Broderick GA; Dmochowski RR; Heaton JP; Lue TF; Milbank AJ; Nehra A; Sharlip ID;
J Urol; 2005 Jul; 174(1):230-9. PubMed ID: 15947645
[No Abstract] [Full Text] [Related]
60. Clinical evaluation of erectile dysfunction in the era of PDE-5 inhibitors.
Lobo JR; Nehra A
Urol Clin North Am; 2005 Nov; 32(4):447-55, vi. PubMed ID: 16291036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
